These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1191 related articles for article (PubMed ID: 26901614)
1. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Yang CY; Lin MW; Chang YL; Wu CT; Yang PC Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614 [TBL] [Abstract][Full Text] [Related]
2. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Yang CY; Lin MW; Chang YL; Wu CT; Yang PC Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. Chang YL; Yang CY; Lin MW; Wu CT; Yang PC Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388 [TBL] [Abstract][Full Text] [Related]
5. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. Chang YL; Yang CY; Lin MW; Wu CT; Yang PC Eur J Cancer; 2016 Jun; 60():125-35. PubMed ID: 27107327 [TBL] [Abstract][Full Text] [Related]
6. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer. Yang CY; Lin MW; Chang YL; Wu CT Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791 [TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796 [TBL] [Abstract][Full Text] [Related]
8. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405 [No Abstract] [Full Text] [Related]
9. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381 [TBL] [Abstract][Full Text] [Related]
10. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872 [TBL] [Abstract][Full Text] [Related]
11. Aligning digital CD8 Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764 [TBL] [Abstract][Full Text] [Related]
12. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403 [TBL] [Abstract][Full Text] [Related]
14. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240 [TBL] [Abstract][Full Text] [Related]
15. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes. Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439 [TBL] [Abstract][Full Text] [Related]
16. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Cho YA; Yoon HJ; Lee JI; Hong SP; Hong SD Oral Oncol; 2011 Dec; 47(12):1148-53. PubMed ID: 21911310 [TBL] [Abstract][Full Text] [Related]
17. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis. Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]